[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE602004017474D1 - Isethionat salz eines selektiven cdk4 inhibitors - Google Patents

Isethionat salz eines selektiven cdk4 inhibitors

Info

Publication number
DE602004017474D1
DE602004017474D1 DE602004017474T DE602004017474T DE602004017474D1 DE 602004017474 D1 DE602004017474 D1 DE 602004017474D1 DE 602004017474 T DE602004017474 T DE 602004017474T DE 602004017474 T DE602004017474 T DE 602004017474T DE 602004017474 D1 DE602004017474 D1 DE 602004017474D1
Authority
DE
Germany
Prior art keywords
cdk4 inhibitor
selective cdk4
isethionate salt
isethionate
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004017474T
Other languages
English (en)
Inventor
Vladimir Genukh Beylin
Anthony Clyde Blackburn
David Thomas Erdman
Peter Laurence Toogood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of DE602004017474D1 publication Critical patent/DE602004017474D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602004017474T 2003-07-11 2004-06-28 Isethionat salz eines selektiven cdk4 inhibitors Expired - Lifetime DE602004017474D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48635103P 2003-07-11 2003-07-11
PCT/IB2004/002152 WO2005005426A1 (en) 2003-07-11 2004-06-28 Isethionate salt of a selective cdk4 inhibitor

Publications (1)

Publication Number Publication Date
DE602004017474D1 true DE602004017474D1 (de) 2008-12-11

Family

ID=34062121

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004017474T Expired - Lifetime DE602004017474D1 (de) 2003-07-11 2004-06-28 Isethionat salz eines selektiven cdk4 inhibitors

Country Status (32)

Country Link
US (2) US7345171B2 (de)
EP (1) EP1648889B1 (de)
JP (1) JP4053073B2 (de)
KR (1) KR100816945B1 (de)
CN (1) CN1835951B (de)
AR (1) AR045898A1 (de)
AT (1) ATE412650T1 (de)
AU (1) AU2004255934B2 (de)
BR (1) BRPI0412516A (de)
CA (1) CA2532049C (de)
CL (1) CL2004001701A1 (de)
CY (1) CY1108589T1 (de)
DE (1) DE602004017474D1 (de)
DK (1) DK1648889T3 (de)
ES (1) ES2313016T3 (de)
GT (1) GT200400130A (de)
HK (1) HK1091205A1 (de)
IL (1) IL173034A (de)
MX (1) MXPA06000484A (de)
NL (1) NL1026624C2 (de)
NO (1) NO335100B1 (de)
NZ (1) NZ544609A (de)
PA (1) PA8606501A1 (de)
PE (1) PE20050700A1 (de)
PL (1) PL1648889T3 (de)
PT (1) PT1648889E (de)
RU (1) RU2317296C2 (de)
SI (1) SI1648889T1 (de)
TW (1) TWI288750B (de)
UY (1) UY28404A1 (de)
WO (1) WO2005005426A1 (de)
ZA (1) ZA200600230B (de)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060111716A (ko) 2002-01-22 2006-10-27 워너-램버트 캄파니 엘엘씨 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
EP1740184A1 (de) * 2004-03-30 2007-01-10 Pfizer Products Incorporated Kombinationen von signalübertragungshemmern
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
CN101395155A (zh) * 2005-10-07 2009-03-25 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
MX2009002069A (es) 2006-09-08 2009-03-06 Pfizer Prod Inc Sintesis de 2-(piridin-2-ilamino)pirido[2,3-d]pirimidin-7-onas.
PT2074122E (pt) 2006-09-15 2011-08-24 Pfizer Prod Inc Compostos de pirido(2,3-d)-pirimidinona e sua utilização como inibidores de pi3
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
AU2007333791A1 (en) * 2006-12-14 2008-06-26 Panacea Pharmaceuticals, Inc. Methods of neuroprotection by cyclin-dependent kinase inhibition
WO2009061345A2 (en) * 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
JP5537439B2 (ja) 2007-12-19 2014-07-02 アムジエン・インコーポレーテツド 細胞周期阻害剤としての縮合ピリジン、ピリミジンおよびトリアジン化合物
MX2010010975A (es) * 2008-04-07 2010-11-01 Amgen Inc Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
CN102231984A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
WO2010051127A2 (en) * 2008-10-01 2010-05-06 The University Of North Carolina At Chapel Hill Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
EA022924B1 (ru) 2009-04-03 2016-03-31 Ф.Хоффманн-Ля Рош Аг ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
AU2010248886A1 (en) 2009-05-13 2011-12-01 The University Of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
CA2780190C (en) 2009-11-06 2020-05-05 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
CA2786002C (en) 2009-12-31 2018-10-02 Joaquin Pastor Fernandez Tricyclic compounds for use as kinase inhibitors
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
CA2818046A1 (en) * 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
LT2672967T (lt) 2011-02-07 2018-12-10 Plexxikon Inc. Junginiai ir būdai skirti kinazės moduliavimui, ir jų indikacijos
AU2012230896B9 (en) 2011-03-23 2015-06-18 Amgen Inc. Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
CN103534867B (zh) 2011-06-17 2017-04-12 流体公司 含有磺酸根离子的离子液体
CA2868966C (en) 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2014128588A1 (en) * 2013-02-21 2014-08-28 Pfizer Inc. Solid forms of a selective cdk4/6 inhibitor
CN105473140B (zh) 2013-03-15 2018-04-10 G1治疗公司 在化学疗法期间对正常细胞的瞬时保护
CA3152117A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
AU2014235462C1 (en) * 2013-03-15 2018-11-01 Concert Pharmaceuticals, Inc. Deuterated palbociclib
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
US9717735B2 (en) 2014-04-17 2017-08-01 G1 Therapeutics, Inc. Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
CN105294681B (zh) * 2014-07-26 2017-07-07 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
WO2016016769A1 (en) * 2014-07-31 2016-02-04 Sun Pharmaceutical Industries Limited A process for the preparation of palbociclib
US20170240543A1 (en) * 2014-08-14 2017-08-24 Sun Pharmaceutical Industries Limited Crystalline forms of palbociclib
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3191098A4 (de) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Kombinationen und dosierschemen zur behandlung von rb-positiven tumoren
CN105622638B (zh) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
WO2016066420A1 (en) * 2014-10-29 2016-05-06 Sandoz Ag Crystalline forms of palbociclib monohydrochloride
CN105616419A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂固体分散体的药物组合物及其制备方法
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
EP4183806A3 (de) 2014-11-12 2023-08-02 Seagen Inc. Glycaninteragierende verbindungen und verfahren zur verwendung
WO2016090257A1 (en) * 2014-12-05 2016-06-09 Crystal Pharmatech Inc. Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
WO2016092442A1 (en) * 2014-12-08 2016-06-16 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline forms of palbociclib acetate
CN105732615B (zh) * 2014-12-31 2018-05-01 山东轩竹医药科技有限公司 Cdk激酶抑制剂
AU2016214897B9 (en) 2015-02-03 2020-06-04 Jiangsu Hengrui Medicine Co., Ltd. Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor
CZ201589A3 (cs) 2015-02-11 2016-08-24 Zentiva, K.S. Pevné formy soli Palbociclibu
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
EP3078663A1 (de) 2015-04-09 2016-10-12 Sandoz Ag Modifizierte partikel von palbociclib
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
CN104910149A (zh) * 2015-04-28 2015-09-16 上海百奇医药科技有限公司 一种Palbociclib制备方法
CN106117199A (zh) * 2015-05-04 2016-11-16 江苏恒瑞医药股份有限公司 一种细胞周期蛋白依赖性激酶抑制剂的二羟乙基磺酸盐、其结晶形式及其制备方法
ES2893478T3 (es) * 2015-05-29 2022-02-09 Teijin Pharma Ltd Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable del mismo
LT3302565T (lt) * 2015-06-04 2019-12-27 Pfizer Inc. Kietos palbociklibo dozavimo formos
CN106317053A (zh) * 2015-06-29 2017-01-11 北大方正集团有限公司 一种帕博昔布晶型a的制备方法
US10526326B2 (en) 2015-08-05 2020-01-07 Ratiopharm Gmbh Crystalline form and acetic acid adducts of palbociclib
CN105085517B (zh) * 2015-08-06 2016-11-23 天津华洛康生物科技有限公司 一种结晶型帕博西尼游离碱水合物及其制备方法
CN106474129A (zh) * 2015-09-01 2017-03-08 上海方楠生物科技有限公司 一种帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法
HU230962B1 (hu) 2015-10-28 2019-06-28 Egis Gyógyszergyár Zrt. Palbociclib sók
EP3373969A4 (de) 2015-11-12 2019-08-14 Siamab Therapeutics, Inc. Glycaninteragierende verbindungen und verfahren zur verwendung
CN105418603A (zh) * 2015-11-17 2016-03-23 重庆莱美药业股份有限公司 一种高纯度帕布昔利布及其反应中间体的制备方法
CN106800553A (zh) * 2015-11-26 2017-06-06 上海科胜药物研发有限公司 一种帕博西尼二羟乙基磺酸盐的晶型
CN106800554A (zh) * 2015-11-26 2017-06-06 上海科胜药物研发有限公司 一种帕博西尼二盐酸盐的晶型及其制备方法
CN105541832A (zh) * 2015-12-15 2016-05-04 南京艾德凯腾生物医药有限责任公司 一种羟乙基磺酸盐帕布昔利布的制备方法
WO2017130219A1 (en) 2016-01-25 2017-08-03 Mylan Laboratories Limited Amorphous solid dispersion of palbociclib
WO2017145054A1 (en) 2016-02-24 2017-08-31 Lupin Limited Modified particles of crystalline palbociclib free base and process for the preparation thereof
CN107137408A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种cdk4/6抑制剂与芳香化酶抑制剂联合在制备治疗乳腺癌的药物中的用途
CN107137409A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种cdk4/6抑制剂与雌激素受体拮抗剂联合在制备治疗乳腺癌的药物中的用途
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
WO2017172734A1 (en) * 2016-03-29 2017-10-05 Mayo Foundation For Medical Education And Research Treating cancer metastasis
WO2018001270A1 (en) * 2016-06-30 2018-01-04 Noratech Pharmaceuticals, Inc. Palbociclib prodrugs and composition thereof
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
MX2019000246A (es) * 2016-07-07 2019-05-27 Plantex Ltd Formas en estado solido del dimesilato de palbociclib.
RS61934B1 (sr) 2016-08-15 2021-07-30 Pfizer Inhibitori piridopirimdinona cdk2/ 4/6
US10710999B2 (en) 2016-10-07 2020-07-14 Mylan Laboratories Limited Polymorph of an intermediate for palbociclib synthesis
WO2018073574A1 (en) 2016-10-20 2018-04-26 Cipla Limited Polymorphic forms of palbociclib
KR20190071763A (ko) 2016-10-20 2019-06-24 화이자 인코포레이티드 폐 동맥 고혈압을 치료하기 위한 항증식제
US20190275049A1 (en) 2016-11-16 2019-09-12 Pfizer Inc. Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
EP3541847A4 (de) 2016-11-17 2020-07-08 Seattle Genetics, Inc. Glycaninteragierende verbindungen und verfahren zur verwendung
MX2019005717A (es) * 2016-11-28 2019-08-12 Teijin Pharma Ltd Cristal de derivado de pirido [3,4-d] pirimidina o solvato del mismo.
AR110728A1 (es) 2017-01-06 2019-04-24 G1 Therapeutics Inc Terapia combinada para el tratamiento del cáncer
CN110913903B (zh) 2017-03-03 2024-03-01 思进股份有限公司 聚糖相互作用化合物和使用方法
WO2018191950A1 (en) * 2017-04-21 2018-10-25 Alnova Pharmaceuticals, Ltd. Palbociclib compositions and methods thereof
EA201992768A1 (ru) 2017-06-29 2020-05-19 Г1 Терапьютикс, Инк. Морфологические формы g1t38 и способы их получения
WO2019020715A1 (en) 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING PALBOCICLIB
AU2019211491B2 (en) * 2018-01-29 2024-03-14 Beta Pharma, Inc. 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof
CN112041307B (zh) 2018-02-06 2024-02-09 伊利诺伊大学评议会 作为选择性雌激素受体降解剂的取代的苯并噻吩类似物
US20200405809A1 (en) 2018-02-27 2020-12-31 Pfizer Inc. Combination of a cyclin dependent kinase inhibitor and a bet- bromodomain inhibitor
EP3793609B1 (de) 2018-05-14 2023-12-13 Pfizer Inc. Orale lösungsformulierung
AU2019310335A1 (en) 2018-07-23 2021-02-11 F. Hoffmann-La Roche Ag Methods of treating cancer with PI3K inhibitor, GDC-0077
CN112839657A (zh) 2018-08-24 2021-05-25 G1治疗公司 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成
JP6952747B2 (ja) 2018-09-18 2021-10-20 ファイザー・インク がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
CN112839642A (zh) 2018-10-08 2021-05-25 豪夫迈·罗氏有限公司 用PI3Kα抑制剂和二甲双胍治疗癌症的方法
US11424484B2 (en) 2019-01-24 2022-08-23 Octet Scientific, Inc. Zinc battery electrolyte additive
WO2020157709A1 (en) 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
WO2020239558A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
EP3976043A1 (de) 2019-05-24 2022-04-06 Pfizer Inc. Kombinationstherapien mit cdk-hemmern
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
CN110143948B (zh) * 2019-06-21 2021-05-14 上海博悦生物科技有限公司 Cdk4/6抑制剂、其药物组合物、制备方法及应用
AU2020396093A1 (en) 2019-12-03 2022-05-19 Genentech, Inc. Combination therapies for treatment of breast cancer
US20230117684A1 (en) 2020-03-05 2023-04-20 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
KR20230058614A (ko) 2020-07-15 2023-05-03 화이자 인코포레이티드 암 치료를 위한 kat6 억제제 방법 및 조합
WO2022018596A1 (en) 2020-07-20 2022-01-27 Pfizer Inc. Combination therapy
CN114246841B (zh) * 2020-09-24 2024-02-02 南京济群医药科技股份有限公司 一种羟乙磺酸哌柏西利的组合物及药物
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
CN113845520A (zh) * 2021-09-09 2021-12-28 安徽皓元药业有限公司 一种帕布昔利布乳清酸盐及其制备方法
KR20240118134A (ko) 2021-12-10 2024-08-02 일라이 릴리 앤드 캄파니 Cdk4 및 6 억제제로 이전에 치료된 환자에서의 호르몬 수용체-양성, 인간 표피 성장 인자 수용체 2-음성 진행성 또는 전이성 유방암의 치료를 위한 풀베스트란트와 조합된 cdk4 및 6 억제제
WO2023111810A1 (en) 2021-12-14 2023-06-22 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023114264A1 (en) 2021-12-15 2023-06-22 Eli Lilly And Company Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
CN114195784A (zh) * 2021-12-29 2022-03-18 斯坦德标准技术研究(湖北)有限公司 帕博西尼有关物质及其制备方法和应用
EP4302832A1 (de) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib-formulierung, die glucono-delta-lacton enthält
EP4302755A1 (de) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Eine aminosäure enthaltende palbociclib-formulierung
WO2024023703A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
TW202416991A (zh) 2022-08-31 2024-05-01 美商亞文納營運公司 雌激素受體降解劑之給藥方案
TW202432102A (zh) 2022-11-02 2024-08-16 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑
WO2024132652A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024133726A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
WO2024201334A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720332B2 (en) * 2000-09-01 2004-04-13 Smithkline Beecham Corporation Oxindole derivatives
JP2005524609A (ja) * 2001-12-17 2005-08-18 スミスクライン ビーチャム コーポレーション ピラゾロピリダジン誘導体
KR20060111716A (ko) * 2002-01-22 2006-10-27 워너-램버트 캄파니 엘엘씨 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
JP2006503081A (ja) * 2002-10-10 2006-01-26 スミスクライン ビーチャム コーポレーション 化学化合物
DE60324178D1 (de) * 2002-11-22 2008-11-27 Smithkline Beecham Corp THIAZOLIDIN-4-ONES UM hYAK3 PROTEINEN ZU HEMMEN
EP1590341B1 (de) * 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
WO2004076414A2 (en) * 2003-02-27 2004-09-10 Smithkline Beecham Corporation Novel compounds

Also Published As

Publication number Publication date
IL173034A0 (en) 2006-06-11
ES2313016T3 (es) 2009-03-01
RU2006101052A (ru) 2006-07-27
ZA200600230B (en) 2007-04-25
CN1835951B (zh) 2010-06-02
MXPA06000484A (es) 2006-04-05
NO335100B1 (no) 2014-09-15
UY28404A1 (es) 2005-02-28
DK1648889T3 (da) 2009-01-05
AU2004255934B2 (en) 2010-02-25
SI1648889T1 (sl) 2009-02-28
WO2005005426A1 (en) 2005-01-20
NZ544609A (en) 2008-07-31
KR100816945B1 (ko) 2008-03-25
NO20060386L (no) 2006-04-05
CA2532049A1 (en) 2005-01-20
CL2004001701A1 (es) 2005-06-03
CA2532049C (en) 2010-07-20
PT1648889E (pt) 2008-12-10
PL1648889T3 (pl) 2009-03-31
US7863278B2 (en) 2011-01-04
US20050059670A1 (en) 2005-03-17
JP2007530425A (ja) 2007-11-01
JP4053073B2 (ja) 2008-02-27
CN1835951A (zh) 2006-09-20
BRPI0412516A (pt) 2006-09-19
US7345171B2 (en) 2008-03-18
NL1026624A1 (nl) 2005-01-12
NL1026624C2 (nl) 2005-07-20
GT200400130A (es) 2005-07-14
HK1091205A1 (en) 2007-01-12
CY1108589T1 (el) 2014-04-09
PE20050700A1 (es) 2005-10-18
TW200516079A (en) 2005-05-16
EP1648889A1 (de) 2006-04-26
AU2004255934A1 (en) 2005-01-20
EP1648889B1 (de) 2008-10-29
AR045898A1 (es) 2005-11-16
TWI288750B (en) 2007-10-21
KR20060054300A (ko) 2006-05-22
PA8606501A1 (es) 2005-03-03
US20080021037A1 (en) 2008-01-24
IL173034A (en) 2010-06-16
RU2317296C2 (ru) 2008-02-20
ATE412650T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
ATE412650T1 (de) Isethionat salz eines selektiven cdk4 inhibitors
ATE373003T1 (de) Phosphorsäuresalz eines dipeptidylpeptidase-iv- inhibitors
ATE534645T1 (de) Kaliumsalz eines hiv-integrasehemmers
CY2016042I1 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
DK2439205T3 (da) Carboxamidforbindelser og deres anvendelse som calpaininhibitorer
IS7483A (is) Bensamíðafleiður gagnlegar sem históndeasetýlasatálmar
ATE425152T1 (de) Aminocarbonylderivate als histone-deacetylase- inhibitoren
DK2094263T3 (da) 2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer
CY2013042I2 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
ATE395343T1 (de) Sulfonylderivate als histone-deacetylase- inhibitoren
SE0502338L (sv) Azaspiroalkanderivat som hämmare av metalloproteaser
DK1912949T3 (da) Cyclohexylaminisoquinolon-derivater som inhibitorer af rho-kinase
ITVA20050027A1 (it) Metodo di generazione di successioni di numeri o bit pseudo casuali
DE602006018355D1 (de) Transdermale verabreichung eines meptazinolsalzes
DK1848430T3 (da) Nye benzylamin-derivativer som cetp-inhibitors
DE602005025499D1 (de) Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
DE60320933D1 (de) Rho-kinase inhibitoren
NO20043793L (no) Nikotinamidderivater anvendelige som PDE4 inhibitorer
DK1585749T3 (da) Diazepinoindol-derivater som kinaseinhibitorer
IS8242A (is) Nikótínamíð afleiður nytsamlegar sem PDE4 hindrar
DK1501804T3 (da) Isoquinolinderivat MAO-B-inhibitorer
DE50311093D1 (de) Lagefixierung eines bolzens
DK1511718T3 (da) N-acylaminobenzenderivater som selektive monoaminoxidase B-inhibitorer
ATE549318T1 (de) Aminsalz eines carbostyrylderivates
DE602006008015D1 (de) Feste salzformen eines pyrrolsubstituierten 2-indolinons

Legal Events

Date Code Title Description
8364 No opposition during term of opposition